The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
Darrick K LiYanjie RenDaniel S FiererStephanie RutledgeObaid S ShaikhVincent Lo ReTracey G SimonAbdul-Badi Abou-SamraRaymond T ChungAdeel A ButtPublished in: Hepatology (Baltimore, Md.) (2018)
DAA treatment is not associated with a higher risk of HCC in persons with cirrhosis with chronic HCV infection in the short term. Previously reported higher rates of HCC associated with DAA treatment may be explained by both the presence of relatively fewer baseline HCC risk factors in persons treated with IFN as well as selection bias, given that DAA regimens were used to treat persons at higher risk for developing HCC. (Hepatology 2018;67:2244-2253).
Keyphrases